Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial

Introduction: First-line treatment of EGFR-mutated NSCLC with erlotinib plus antiangiogenic inhibitor exhibits promising results. However, the efficacy of this combination has not been fully investigated. Therefore, we evaluated the efficacy and safety of osimertinib plus bevacizumab in patients wit...

Full description

Bibliographic Details
Main Authors: Makoto Hibino, MD, Osamu Hiranuma, MD, Yoshizumi Takemura, MD, PhD, Yuki Katayama, MD, Yusuke Chihara, MD, PhD, Taishi Harada, MD, Kohei Fujita, MD, PhD, Toshiyuki Kita, MD, PhD, Nobuyo Tamiya, MD, PhD, Takeshi Tsuda, MD, Shinsuke Shiotsu, MD, Yukihiro Tamura, MD, PhD, Takashi Aoyama, MD, Yoichi Nakamura, MD, PhD, Masaaki Terashima, MD, PhD, Yoshie Morimoto, MD, PhD, Kazuhiro Nagata, MD, PhD, Kenichi Yoshimura, PhD, Junji Uchino, MD, PhD, Koichi Takayama, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:JTO Clinical and Research Reports
Subjects:
Angiogenesis inhibitor
Bevacizumab
EGFR tyrosine kinase inhibitors
Osimertinib
Vascular endothelial growth factor
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001485

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001485

Similar Items